{"filing":{"accession_number":"0001437749-26-023916","cik":"0001533040","ticker":"PHIO","company_name":"Phio Pharmaceuticals Corp.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"phio20260717_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926023916/phio20260717_8k.htm"},"events":[{"id":18949,"run_id":17049,"accession_number":"0001437749-26-023916","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Phio Pharmaceuticals appointed R. Todd Plott, M.D. to its Board of Directors effective July 20, 2026, increasing the board size to six members. Dr. Plott brings 30+ years of dermatologic experience and prior FDA advisory committee service, directly relevant to the company's clinical-stage development of PH-762 for skin cancers.","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":17912,"accession_number":"0001437749-26-023916","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of R. Todd Plott, M.D. to the Board of Directors effective July 20, 2026, with the Board size increased to six members. Dr. Plott brings 30+ years of dermatologic experience and prior FDA advisory committee service, directly relevant to the company's clinical-stage development of PH-762 for skin cancers. This is a material governance event affecting board composition and strategic oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:08:40.533785+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17913,"accession_number":"0001437749-26-023916","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. R. Todd Plott, M.D. to the Board of Directors of Phio Pharmaceuticals. The press release emphasizes his extensive qualifications, including 30+ years of dermatologic experience, FDA advisory committee service, and clinical trial expertise directly relevant to the company's lead program PH-762 for squamous cell carcinoma. This is a material board appointment that would affect investor assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:08:40.533785+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17912,"accession_number":"0001437749-26-023916","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of R. Todd Plott, M.D. to the Board of Directors effective July 20, 2026, with the Board size increased to six members. Dr. Plott brings 30+ years of dermatologic experience and prior FDA advisory committee service, directly relevant to the company's clinical-stage development of PH-762 for skin cancers. This is a material governance event affecting board composition and strategic oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:08:40.533785+00:00","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-07-21"},{"id":17913,"accession_number":"0001437749-26-023916","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. R. Todd Plott, M.D. to the Board of Directors of Phio Pharmaceuticals. The press release emphasizes his extensive qualifications, including 30+ years of dermatologic experience, FDA advisory committee service, and clinical trial expertise directly relevant to the company's lead program PH-762 for squamous cell carcinoma. This is a material board appointment that would affect investor assessment of governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:08:40.533785+00:00","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-07-21"}]}